

Lampalizumab

Cat. No.:	HY-P99298
CAS No.:	1278466-20-8
Target:	Complement System
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Lampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research ^{[1][2]} .
IC ₅₀ & Target	Factor D ^[1]
In Vivo	Lampalizumab delivered intravenously to cynomolgus monkeys elicits nearly 10-fold increases in serum Factor D levels within five hours, effectively neutralizing its inhibitory activity ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Yuan X, et al. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. *Haematologica*. 2017 Mar;102(3):466-475.
- [2]. Hanus J, et al. Current therapeutic developments in atrophic age-related macular degeneration. *Br J Ophthalmol*. 2016 Jan;100(1):122-7.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA